2012 Newest Biotech Trend
The following video is part of our "Motley Fool Conversations" series, in which David Williamson, health-care editor and analyst, and Brendan Byrnes, industrials editor and analyst, discuss topics across the investing world.
In today's edition, David and Brendan discuss the recent trend of biotech companies teaming up with generic manufacturers to create generic biologic drugs. There is currently no easy pathway to approval for biosimilars, but with one potentially coming thanks to the Affordable Care Act, we could see an increase of the cheaper drugs. How will this impact the industry going forward? Watch and find out.
Looking for our prediction for 2012? Check out The Motley Fool's brand-new report, "The Motley Fool's Top Stock for 2012." It highlights a company that is revolutionizing commerce in Latin America. You can get instant access to the name of this company by clicking here -- it's free.
At the time this article was published David Williamson and Brendan Byrnes do not own shares of the companies listed above. The Motley Fool owns shares of Abbott Laboratories, Momenta Pharmaceuticals and Teva Pharmaceutical Industries.Motley Fool newsletter services recommendMomenta Pharmaceuticals. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.